Is alpha-lipoic acid worth taking for neuropathy or weight loss?
Alpha-lipoic acid (ALA) is often sold with two appealing promises: less nerve discomfort and easier weight loss. Whether it is worth taking depends on which outcome matters to you, how long you expect a benefit to last, and your safety risks. Short-term symptom changes do not establish lasting nerve repair, and a small average weight change in a study does not predict your result.
Check which “ALA” you are reading about
This article concerns alpha-lipoic acid, also called thioctic acid. The abbreviation ALA also refers to alpha-linolenic acid, an omega-3 fatty acid. They are different substances. Read the full ingredient name rather than treating advice about one as evidence for the other.
Start with the outcome you want
Before deciding whether to start or reorder ALA, name the outcome you would judge. A weight change, less pain and better nerve function require different evidence.
| Your goal or situation | What to clarify first |
|---|---|
| Long-term diabetic nerve symptom relief | How does the six-month evidence affect your treatment options? |
| Weight loss | Would a small, uncertain additional change justify the cost and risks? |
| Insulin, diabetes medicines or other regular treatment | Can a clinician or pharmacist review interactions and low-glucose risk? |
Weight loss: keep the size of the finding in view
A 2017 meta-analysis of randomized trials estimated about 1.27 kg more weight loss with ALA than placebo on average, with a confidence interval of 0.25 to 2.29 kg. The authors described the effect as small and short-term. An average difference across varied studies is not a personal target or a guaranteed result.
A 24-week randomized trial enrolled 81 adults with overweight or obesity and elevated triglycerides. It studied R-alpha-lipoic acid and found a BMI reduction compared with placebo, but no improvement in its primary triglyceride outcome. Its eligibility criteria excluded people with several medical conditions and treatments. Such a selected trial cannot establish that every supplement formulation benefits every reader, or that weight changes persist after use ends.
Why neuropathy claims can sound contradictory
Older trials did find short-term improvements in diabetic neuropathy symptoms. The SYDNEY 2 trial studied oral ALA for five weeks in 181 people with diabetes and reported greater reductions in symptom scores than placebo. The earlier SYDNEY trial used intravenous treatment over three weeks in 120 participants and also reported improvement. An infusion study cannot be transferred directly to a supplement capsule.
The 2024 Cochrane review asked a longer-term question. It included three trials involving 816 adults, with treatment lasting at least six months. At six months, ALA probably had little or no effect on neuropathy symptoms and may have had little or no effect on impairment. The evidence had limitations, including participant loss during follow-up. The review found no studies reporting quality of life or complications such as ulcers or amputations.
These findings concern different treatment periods and outcomes. They do not justify promising that ALA rebuilds damaged nerves. If your goal is sustained relief, better walking or fewer complications, discuss evidence for that specific goal rather than relying on an “antioxidant” label.
Safety includes a rare low-blood-sugar problem
NCCIH lists headache, heartburn, nausea and vomiting among common adverse effects. A product being called natural does not settle whether it fits your medication list or medical history.
An official Spanish oral ALA medicine label warns that insulin and other diabetes medicines’ glucose-lowering effects may be enhanced. Ask your clinician about interactions and monitoring before adding ALA; do not change prescribed medicines yourself. Medicine-label information informs a safety discussion rather than a supplement dosing plan.
Health Canada concluded that ALA may cause insulin autoimmune syndrome (IAS), which can produce low blood sugar. IAS involves antibodies to the body’s own insulin and can occur without injected insulin. Reported cases appeared rare and involved a specific genetic variation. The 2021 EFSA opinion likewise identified risk in genetically susceptible people and could not establish a dose below which IAS would not occur. This does not mean everyone will develop it; it means a lower amount cannot be presented as eliminating that risk.
If sweating, dizziness, paleness or confusion occur while taking ALA, stop the product and seek medical advice promptly, as Health Canada advises. Severe confusion, fainting or seizures require emergency help. Do not interpret an unexplained episode as proof that the supplement is successfully “improving glucose control.”
Bring symptoms and the label to the appointment
New or persistent numbness deserves assessment before selecting a supplement. NIDDK explains that clinicians may investigate other causes, including thyroid problems, kidney disease or low vitamin B12. ALA is not a substitute for finding the cause or following prescribed diabetes care.
Bring the full product label, medicine list and a brief symptom record. Ask what outcome you would monitor, when to review it, and what would make you reconsider continuing. Pregnancy, breastfeeding and use in children also call for professional advice rather than borrowing an adult trial’s regimen.
Related guides
- Berberine evidence, interactions and risks
- How to check supplement–medicine interactions
- How to read a supplement label
- How to verify supplement quality claims
General health information; this article does not replace medical assessment or prescribe a supplement dose. Sources checked: 30 September 2026.
An illustrative stock photo for reviewing supplement information; it does not demonstrate an alpha-lipoic acid treatment effect. Photo: Etienne Boulanger / Unsplash.
